Cronos Group (CRON) Stock Price, News & Analysis

Company Overview

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Key Stats

• Today's Range: $2.09 to $2.12
• 50-Day Range: $2.08 to $2.34
• 52-Week Range: $1.72 to $3.14
• Volume: 458,924 shs
• Average Volume: 1.93 million shs
• Market Capitalization: $799.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Sell

Cronos Group Stock Analysis - MarketRank™

Cronos Group scored higher than 37% of companies evaluated by MarketBeat, and ranked 795th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Sell

Consensus Rating

Cronos Group has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cronos Group has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cronos Group are expected to grow in the coming year, from ($0.05) to $0.01 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cronos Group is -13.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cronos Group is -13.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cronos Group has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.46% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Cronos Group has recently decreased by 1.20%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cronos Group does not currently pay a dividend.

Dividend Growth

Cronos Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.46% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Cronos Group has recently decreased by 1.20%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.94

News Sentiment

Cronos Group has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cronos Group this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for CRON on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

5 people have added Cronos Group to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cronos Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Cronos Group is held by insiders.

Percentage Held by Institutions

Only 8.71% of the stock of Cronos Group is held by institutions.

CRON Stock Analysis - Frequently Asked Questions

How have CRON shares performed this year?

Cronos Group's stock was trading at $2.09 on January 1st, 2024. Since then, CRON stock has increased by 0.0% and is now trading at $2.09.
View the best growth stocks for 2024 here.

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.02) EPS for the quarter. The business earned $27.76 million during the quarter, compared to analysts' expectations of $25.85 million. Cronos Group had a negative trailing twelve-month return on equity of 2.06% and a negative net margin of 56.43%.

Who are Cronos Group's major shareholders?

Top institutional investors of Cronos Group include Intact Investment Management Inc. (0.10%) and International Assets Investment Management LLC (0.01%).
View institutional ownership trends.

How do I buy shares of Cronos Group?

Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cronos Group investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 10/31/2024
• Next Earnings (Confirmed): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRON
• CUSIP: N/A
• CIK: 1656472
• Web: www.thecronosgroup.com
• Phone: (416) 504-0004
• Fax: N/A
• Employees: 356
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.50
• Low Stock Price Target: $2.50
• Potential Upside/Downside: +43.5%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-73,960,000.00
• Net Margins: -56.43%
• Pretax Margin: -61.24%
• Return on Equity: -2.06%
• Return on Assets: -1.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 28.29
• Quick Ratio: 27.41

Sales & Book Value

• Annual Sales: $101.78 million
• Price / Sales: 7.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.87 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 382,295,000
• Free Float: 355,917,000
• Market Cap: $799.00 million
• Optionable: Optionable
• Beta: 0.97